| 0.285 -0.014 (-4.68%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.35 | 1-year : | 0.38 |
| Resists | First : | 0.3 | Second : | 0.33 |
| Pivot price | 0.28 |
|||
| Supports | First : | 0.27 | Second : | 0.22 |
| MAs | MA(5) : | 0.29 |
MA(20) : | 0.29 |
| MA(100) : | 0.28 |
MA(250) : | 0.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 45 |
D(3) : | 49.1 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 0.5 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IGC ] has closed above bottom band by 28.3%. Bollinger Bands are 55.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.3 - 0.3 | 0.3 - 0.3 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.28 - 0.28 | 0.28 - 0.29 |
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Tue, 09 Jun 2026
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts - BioSpace
Mon, 08 Jun 2026
IGC Pharma Extends $12 Million O-Bank Credit Facility; Increases Fee to $60,000 - TradingView
Mon, 08 Jun 2026
IGC Pharma (NYSE: IGC) extends $12M O-Bank loan facility with higher fee - Stock Titan
Mon, 08 Jun 2026
IGC Pharma, Inc. Enters Into Amendment To Extend Master Loan And Security Agreement With O-Bank Co., Ltd - marketscreener.com
Mon, 08 Jun 2026
IGC Maintained by Ascendiant Capital -- Price Target Raised to $5.50 - GuruFocus
Tue, 02 Jun 2026
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|